Q301 - ClonoSEQ Measurable Residual Disease (MRD) Testing Services

Notice of Intent to Sole-Source Requirement: The Department of Veterans Affairs, Network Contracting Office (NCO) 10, intends to negotiate a sole source contract under Simplified Acquisition Procedures and the authority of FAR 6.302-1, Only one responsible source and no other supplies or services will satisfy agency requirements. The associated NAICS code for this is 621511, Size Standard is $41.5 Million. The Product Service Code (PSC) is Q301. The sole-source contract will be awarded to: ADAPTIVE BIOTECHNOLOGIES CORPORATION UEI: DMW5BNQ331K9 Description of requirements: The VA Northeast Ohio Healthcare System (VANEOHS), Pathology and Laboratory Medicine Service (PALMS), requires molecular minimal residual disease (MRD) testing services utilizing the clonoSEQ Assay provided exclusively by Adaptive Biotechnologies. The clonoSEQ Assay is a proprietary, patented molecular test developed and performed exclusively by Adaptive Biotechnologies. Adaptive Biotechnologies is the sole source provider of clonoSEQ MRD testing within the United States. It is the Government's belief that only the proposed candidate possesses the required capabilities to successfully meet this requirement. It is the Government's intention to solicit and negotiate with only this source. This notice of intent is not a request for competitive proposals. IAW FAR 5.207 all responsible sources may submit a capability statement, proposal, or quotation, which shall be considered by the agency. This is not a solicitation or request for offers. No solicitation package is available. Any response to this notice must show clear and convincing evidence that demonstrates the ability to comply with the requirement and that competition would be advantageous to the Government. The Government will not pay for information submitted. A determination not to compete based on responses to this notice is solely within the discretion of the Government. All responses to this intent to sole source must be emailed to Thomas Bellamy @ [email protected] by 3:00 p.m. EST November 12th, 2025.